Calcitonin gene-related peptide inhibits angiotensin II-induced NADPH oxidase-dependent ROS via the Src/STAT3 signalling pathway.


Journal

Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777

Informations de publication

Date de publication:
06 2020
Historique:
received: 30 07 2019
revised: 18 03 2020
accepted: 26 03 2020
pubmed: 7 5 2020
medline: 30 4 2021
entrez: 7 5 2020
Statut: ppublish

Résumé

We had previously demonstrated that the calcitonin gene-related peptide (CGRP) suppresses the oxidative stress and vascular smooth muscle cell (VSMC) proliferation induced by vascular injury. A recent study also indicated that CGRP protects against the onset and development of angiotensin II (Ang II)-induced hypertension, vascular hypertrophy and oxidative stress. However, the mechanism behind the effects of CGRP on Ang II-induced oxidative stress is unclear. CGRP significantly suppressed the level of reactive oxygen species (ROS) generated by NADPH oxidase in Ang II-induced VSMCs. The Ang II-stimulated activation of both Src and the downstream transcription factor, STAT3, was abrogated by CGRP. However, the antioxidative effect of CGRP was lost following the expression of constitutively activated Src or STAT3. Pre-treatment with H-89 or CGRP

Identifiants

pubmed: 32372557
doi: 10.1111/jcmm.15288
pmc: PMC7294141
doi:

Substances chimiques

Antioxidants 0
Reactive Oxygen Species 0
STAT3 Transcription Factor 0
STAT3 protein, human 0
Angiotensin II 11128-99-7
Calcitonin 9007-12-9
NADPH Oxidases EC 1.6.3.-
src-Family Kinases EC 2.7.10.2
Calcitonin Gene-Related Peptide JHB2QIZ69Z

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6426-6437

Informations de copyright

© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

Références

Can J Physiol Pharmacol. 1999 Aug;77(8):606-17
pubmed: 10543724
J Biol Chem. 2009 Nov 6;284(45):31142-55
pubmed: 19736311
Hypertension. 2014 May;63(5):1056-62
pubmed: 24516108
J Hypertens. 2001 Mar;19(3):441-9
pubmed: 11288814
J Hypertens. 2018 Apr;36(4):876-891
pubmed: 29266061
Hypertension. 2010 Mar;55(3):627-35
pubmed: 20100989
Mol Med Rep. 2016 Jul;14(1):936-42
pubmed: 27220315
Oncogene. 2001 Mar 26;20(13):1601-6
pubmed: 11313907
Endocr Rev. 1996 Oct;17(5):533-85
pubmed: 8897024
Circ Cardiovasc Interv. 2011 Feb 1;4(1):104-11
pubmed: 21325199
Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):981-7
pubmed: 12663375
Am J Physiol Renal Physiol. 2014 Jan 1;306(1):F85-97
pubmed: 24197068
Oncogene. 2004 Oct 18;23(48):8017-23
pubmed: 15489919
Circulation. 2017 Jul 25;136(4):367-383
pubmed: 28446517
J Cell Mol Med. 2020 Jun;24(11):6426-6437
pubmed: 32372557
Sci Rep. 2018 Aug 20;8(1):12424
pubmed: 30127519
Mol Cell Biol. 2016 Oct 28;36(22):2811-2823
pubmed: 27550814
Oncotarget. 2014 May 15;5(9):2529-41
pubmed: 24796733
Antioxid Redox Signal. 2013 Oct 1;19(10):1110-20
pubmed: 22530599
J Mol Cell Cardiol. 2013 Jun;59:55-66
pubmed: 23416515
J Hypertens. 2005 Jan;23(1):113-8
pubmed: 15643132
Nature. 1983 Jul 14-20;304(5922):129-35
pubmed: 6346105
Physiol Rev. 2014 Oct;94(4):1099-142
pubmed: 25287861
Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2176-2190
pubmed: 27634835
Neurosci Lett. 2015 Jun 26;598:52-8
pubmed: 25960317
Am J Physiol Heart Circ Physiol. 2007 Apr;292(4):H1714-21
pubmed: 17071733
J Biol Chem. 2011 Jun 24;286(25):22478-88
pubmed: 21536676
Biochem Biophys Res Commun. 1985 Oct 15;132(1):88-94
pubmed: 2998368
Int J Mol Med. 2017 Jul;40(1):209-216
pubmed: 28560441
Circ Res. 2012 Aug 31;111(6):697-707
pubmed: 22798525
Pharmacol Rev. 2000 Mar;52(1):11-34
pubmed: 10699153
Mol Cell Biochem. 2011 Sep;355(1-2):99-108
pubmed: 21603886
JAKSTAT. 2013 Oct 1;2(4):e25764
pubmed: 24416651
Mol Pharmacol. 2004 Apr;65(4):832-41
pubmed: 15044612
J Hypertens. 2004 Mar;22(3):535-42
pubmed: 15076159
Trends Pharmacol Sci. 2010 Oct;31(10):476-83
pubmed: 20633935
Nat Med. 2002 Nov;8(11):1249-56
pubmed: 12411952

Auteurs

Hong-Min Luo (HM)

Department of Nephrology, Third Hospital, Hebei Medical University, Shijiazhuang, China.

Xia Wu (X)

The Third Hospital, Hebei Medical University, Shijiazhuang, China.

Xian Xian (X)

Department of Epidemiology and Statistics, School of Public Health, Hebei Key Laboratory of Environment and Human Health, Hebei Medical University, Shijiazhuang, China.

Lu-Yao Wang (LY)

Department of Epidemiology and Statistics, School of Public Health, Hebei Key Laboratory of Environment and Human Health, Hebei Medical University, Shijiazhuang, China.

Liang-Yu Zhu (LY)

Department of Epidemiology and Statistics, School of Public Health, Hebei Key Laboratory of Environment and Human Health, Hebei Medical University, Shijiazhuang, China.

Hong-Yu Sun (HY)

Department of Epidemiology and Statistics, School of Public Health, Hebei Key Laboratory of Environment and Human Health, Hebei Medical University, Shijiazhuang, China.

Lei Yang (L)

Department of Epidemiology and Statistics, School of Public Health, Hebei Key Laboratory of Environment and Human Health, Hebei Medical University, Shijiazhuang, China.

Wen-Xuan Liu (WX)

Department of Epidemiology and Statistics, School of Public Health, Hebei Key Laboratory of Environment and Human Health, Hebei Medical University, Shijiazhuang, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH